Small Business Early Stage Investment

The summary explains the criteria for investment companies, the process by which investment companies would apply and the manner in which the equity financing provided by the SBA could used.

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

September 13 2011
These written comments were submitted to accompany the testimony of BIO's Interim Vice President for State Government Relations Pete Pellerito in support of legislative and regulatory environments that benefit biosciences industry job growth.
April 7 2011
The House Subcommittee on Healthcare and Technology held a hearing on The Creating Jobs Through Small Business Innovation Act of 2011, a bill that would reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which help fund small innovative companies on the brink of new technologies and discoveries.
March 24 2011
BIO submitted letters of support for the American Research and Competitiveness Act of 2011 (HR 942) to the lead House of Representatives sponsors.
November 1 2009
BIO is submitting this letter in response to the request by the United States Trade Representative (USTR) for comments to compile the National Trade Estimate (NTE) Report on Foreign Trade Barriers.
November 15 2008
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 23 2014
BIO announced plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference.
November 13 2013
The Bill will spur capital formation for small public companies
September 30 2013
NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.